SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https: ...

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical ...

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference  Format:Presentation and fi ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23:Structure Therapeutics Inc. (GPCR) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.Structure Therapeutics' shares gained 8.7% over the last three months compared with the S&P 500’s advanced of 7.7%. The company possesses a Momentum Score of B.Rush Enterprises, Inc. (RUSHA) : This ...

Core Viewpoint - Structure Therapeutics Inc. (GPCR) has shown a significant price increase of 17.7% over the past four weeks, with analysts projecting a mean price target of $87.40, indicating an upside potential of 115.8% from the current price of $40.50 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $15.90, where the lowest estimate of $65 suggests a 60.5% increase, and the highest estimate of $118 indicates a potential surge of 191.4% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Prospects - Analysts have shown increasing optimism about GPCR's earnings, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 8.2% over the past month, with no negative revisions, indicating positive earnings momentum [10] Analyst Ratings - GPCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [11]

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside chat: Thursday, September 5 at 10:00 a.m. EDT Cantor Fitzgerald Global Healthcare Conference 2024 Fireside chat: T ...

Structure Therapeutics' lead product candidate is GSBR-1290, a highly selective oral GLP-1 receptor agonist, which is being evaluated in multiple mid-stage studies for treating healthy overweight or obese individuals. The Zacks Consensus Estimate is currently pegged at a loss of 23 cents per share. Let's see how things might have shaped up for the upcoming quarterly release. The company plans to file an investigational new drug application to the FDA in the third quarter of 2024 to begin the phase IIb obesi ...

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion by 2030. After all, there's always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There's even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, gene editing ...

Structure Therapeutics (GPCR 0.84%) and Novo Nordisk (NVO -0.68%) have one big thing in common: the desire to compete in the bustling market for obesity therapies. While the pre-revenue biotech is still a fledgling in the midst of its attempt to develop its first approved medicine, some recently released data suggests that Novo Nordisk might want to keep an eye out. This market won't be winner-take-all That's a tall order, as Novo's trailing-12-month revenue is $35.5 billion, and the cardiometabolic segment ...

The capsule-to-tablet PK study was designed to evaluate the tolerability, safety and pharmacokinetics of a new tablet formulation of GSBR-1290 in the given patient population. Data from the capsule-to-tablet PK study showed that treatment with the tablet formulation of GSBR-1290 led to a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks. Image Source: Zacks Investment Research Obesity has become a global health problem as it can cause heart disease, diabetes and stroke, leading to an exponential i ...